Key dates Information webinar: 6 July 2026, 15:00 to 17:00 CEST Stage 0, Expression of Interest (mandatory): 1 July to 10 September 2026 Stage 1, Short Proposal: 15 September to 29 October 2026 Full details of the ECTC 2026 are available on the ERDERA call page, including the pre-announcement of the call, the official call text and application documents published at the launch on 1 July
Inhibits Lipogenesis (Fat Accumulation) Unlike traditional weight loss methods that rely solely on calorie restriction, AOD-9604 directly prevents new fat deposits from forming
This will allow for more sustained weight loss, and fewer side effects all while avoiding metabolic damage
(More information) Some, but not all, studies have reported that micronutrient supplementation improves overall mood and psychological well-being
It is commonly used alongside other peptides and is administered through subcutaneous injection under clinical guidance
Note: This product is intended for in vitro research purposes only, not for human or animal consumption